Abstract
Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Infectious Disorders - Drug Targets
Title: Proteomics to Study Candida albicans Biology and Pathogenicity
Volume: 6 Issue: 4
Author(s): Derek P. Thomas, Aida Pitarch, Lucia Monteoliva, Concha Gil and Jose L. Lopez-Ribot
Affiliation:
Keywords: Candida albicans, two-dimensional electrophoresis, proteomics, serology, cell wall, immunoproteomics, adhesins, morphogenesis, antifungal resistance
Abstract: Candida albicans is an opportunistic pathogenic fungus capable of causing infections in an expanding population of immunosuppressed patients. The implementation of proteomics in the post-genomic era of this organism can provide vital information about its biological complexity and pathogenic traits. C. albicans proteomic analyses to date have focused on the understanding of the cell wall, virulence, dimorphism, antifungal drug effects and resistance, and serological response, among others. This exciting and rapid growing discipline should become an indispensable tool in C. albicans research, particularly to address problems that cannot be solved by genomic studies. Furthermore, in the near future it is expected that results from proteomic experiments will lead to novel techniques for the management of candidiasis.
Export Options
About this article
Cite this article as:
Thomas P. Derek, Pitarch Aida, Monteoliva Lucia, Gil Concha and Lopez-Ribot L. Jose, Proteomics to Study Candida albicans Biology and Pathogenicity, Infectious Disorders - Drug Targets 2006; 6 (4) . https://dx.doi.org/10.2174/187152606779025815
DOI https://dx.doi.org/10.2174/187152606779025815 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation
Current Cancer Drug Targets P53 Family: At the Crossroads in Cancer Therapy
Current Medicinal Chemistry Current Opinion in the Pharmaceutical Management of Irritable and Inflammatory Bowel Diseases: Role of ATP
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Endocrine and Antineoplastic Actions of Growth Hormone-Releasing Hormone Antagonists
Current Medicinal Chemistry Clinical Use of Rituximab in Patients with HIV Related Lymphoma and Multicentric Castlemans Disease
Current Drug Delivery Exposure of B Cell Chronic Lymphocytic Leukemia (B-CLL) Cells to Nutlin-3 Induces a Characteristic Gene Expression Profile, which Correlates with Nutlin-3-Mediated Cytotoxicity (Supplementry Table)
Current Cancer Drug Targets Erythropoietin in Cancer: An Update
Current Molecular Medicine Microtubule-targeting Anticancer Agents from Marine Natural Substance
Anti-Cancer Agents in Medicinal Chemistry Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Doxorubicin vs. ladirubicin: methods for improving osteosarcoma treatment
Mini-Reviews in Medicinal Chemistry Anti-Angiogenesis Activities of Dietary Constituents and Health Foods with Potential Anti-Hepatocellular Carcinoma Activity
Recent Patents on Biomarkers 2', 4'-dihydroxy-3, 4-methylenedioxychalcone Activate Mitochondrial Apoptosis of Ehrlich Ascites Carcinoma Cells
Current Drug Therapy Cyclin-Dependent Kinase Inhibition by Flavoalkaloids
Mini-Reviews in Medicinal Chemistry Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Arginine Deprivation as a Targeted Therapy for Cancer
Current Pharmaceutical Design Anticancer Properties of Flavonoids: Roles in Various Stages of Carcinogenesis
Cardiovascular & Hematological Agents in Medicinal Chemistry Purine Nucleoside Analogues for the Treatment of Hematological Malignancies: Pharmacology and Clinical Applications
Current Cancer Drug Targets Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Hypocholesterolemia
Current Vascular Pharmacology